SAPHO syndrome: current clinical, diagnostic and treatment approaches

被引:9
|
作者
Yildirim, Tuba Demirci [1 ]
Sari, Ismail [1 ]
机构
[1] Dokuz Eylul Univ, Fac Med, Dept Rheumatol, Izmir, Turkiye
关键词
SAPHO syndrome; Synovitis; Review; Treatment; OSTEITIS SAPHO; SINGLE-CENTER; PROPIONIBACTERIUM-ACNES; FOLLOW-UP; HYPEROSTOSIS; PUSTULOSIS; SYNOVITIS; ARTHRITIS; INJECTION; CYTOKINES;
D O I
10.1007/s00296-023-05491-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review provides an overview of SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis), a rare autoinflammatory disease that primarily affects bones, skin, and joints. We conducted a search on Medline/PubMed using keywords such as SAPHO syndrome, chronic recurrent multifocal osteitis/osteomyelitis, and related terms. SAPHO syndrome is rare, with a reported frequency of 1 in 10,000 in the Caucasian population. However, the actual incidence of SAPHO syndrome is unknown, and the incidence of the disease is likely higher. The pathogenesis of SAPHO syndrome remains incompletely understood. Current evidence suggests that SAPHO results from a complex interplay between immune dysregulation, genetic susceptibility, and environmental factors. It's not clear if SAPHO syndrome is an autoimmune disease or an autoinflammatory disease, but current evidence suggests that it's more likely an autoinflammatory disease because of things like neutrophil hyperactivity, fewer natural killer (NK) cells, high levels of interleukin (IL)-1, and a good response to treatments that block IL-1. Osteo-articular (OA) involvement is a key clinical feature of SAPHO. It affects the anterior chest wall, axial skeleton, peripheral joints, mandible, long bones of the extremities, and pelvis. Dermatological involvement is a common target in SAPHO, with lesions observed in 60-90% of cases. Common skin lesions include psoriasis and acne, with hidradenitis suppurativa and neutrophilic dermatoses being less commonly seen. Other clinical findings include constitutional symptoms caused by systemic inflammation, such as fever, weight loss, and fatigue. There is no specific laboratory finding for SAPHO syndrome. However, during active disease, there may be an increase in positive acute phase markers, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement levels, mild leukocytosis, and thrombocytosis. Diagnosis is crucial for SAPHO syndrome, which lacks a specific diagnostic finding and is often underrecognized. A comprehensive evaluation of a patient's medical history and physical examination is crucial. Treatment options include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional and synthetic disease-modifying agents (cDMARDs and sDMARDs), biological therapies, bisphosphonates, and antibiotics. Biological treatments have emerged as a viable alternative for SAPHO patients who do not respond to conventional treatments.
引用
收藏
页码:2301 / 2313
页数:13
相关论文
共 50 条
  • [21] Clinical and Radiological Characteristics of SAPHO Syndrome
    Colina, Matteo
    Trotta, Francesco
    CURRENT RHEUMATOLOGY REVIEWS, 2013, 9 (01) : 22 - 27
  • [22] The SAPHO syndrome: a clinical and imaging study
    Salles, Meritxell
    Olive, Alejandro
    Perez-Andres, Ricard
    Holgado, Susana
    Mateo, Lourdes
    Riera, Elena
    Tena, Xavier
    CLINICAL RHEUMATOLOGY, 2011, 30 (02) : 245 - 249
  • [23] CURRENT KNOWLEDGE AND FUTURE PROSPECTS FOR SAPHO SYNDROME
    Kim, C.
    DRUGS OF TODAY, 2014, 50 (11) : 757 - 761
  • [24] Successful Treatment of SAPHO Syndrome With Ibandronate
    Soyfoo, Muhammad S.
    Gangji, Valerie
    Margaux, Joelle
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (05) : 253 - 253
  • [25] Pamidronate: a novel treatment for the SAPHO syndrome?
    Marshall, H
    Bromilow, J
    Thomas, AL
    Arden, NK
    RHEUMATOLOGY, 2002, 41 (02) : 231 - U3
  • [26] Successful treatment of SAPHO syndrome with apremilast
    Adamo, S.
    Nilsson, J.
    Krebs, A.
    Steiner, U.
    Cozzio, A.
    French, L. E.
    Kolios, A. G. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 959 - 962
  • [27] Pamidronate in the treatment of childhood SAPHO syndrome
    Kerrison, C
    Davidson, JE
    Cleary, AG
    Beresford, MW
    RHEUMATOLOGY, 2004, 43 (10) : 1246 - 1251
  • [28] Efficacy of pamidronate in the treatment of SAPHO syndrome
    Sayag-Boukris, V
    Laoussadi, S
    Cormier, C
    Laroche, F
    Menkès, CJ
    Kahan, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S114 - S114
  • [29] Etanercept in the treatment of refractory SAPHO syndrome
    Zhang, Lei
    Gao, Zhaomeng
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 5 (04): : 62 - 66
  • [30] Efficacy of alendronate in the treatment of the SAPHO syndrome
    Fioravanti, Antonella
    Cantarini, Luca
    Burroni, Luca
    Mazzei, Maria Antonietta
    Volterrani, Luca
    Galeazzi, Mauro
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (03) : 183 - 184